GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (CHIX:CANTAs) » Definitions » EV-to-EBITDA

Cantargia AB (CHIX:CANTAS) EV-to-EBITDA : -2.27 (As of Sep. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cantargia AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cantargia AB's enterprise value is kr509.93 Mil. Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was kr-224.20 Mil. Therefore, Cantargia AB's EV-to-EBITDA for today is -2.27.

The historical rank and industry rank for Cantargia AB's EV-to-EBITDA or its related term are showing as below:

CHIX:CANTAs' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.26   Med: 0   Max: 0
Current: -2.27

CHIX:CANTAs's EV-to-EBITDA is ranked worse than
100% of 461 companies
in the Biotechnology industry
Industry Median: 8.62 vs CHIX:CANTAs: -2.27

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-26), Cantargia AB's stock price is kr4.174. Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was kr-1.300. Therefore, Cantargia AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Cantargia AB EV-to-EBITDA Historical Data

The historical data trend for Cantargia AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB EV-to-EBITDA Chart

Cantargia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.89 -32.44 -3.55 -0.24 -1.78

Cantargia AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 -1.73 -1.78 -2.10 -3.22

Competitive Comparison of Cantargia AB's EV-to-EBITDA

For the Biotechnology subindustry, Cantargia AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cantargia AB's EV-to-EBITDA falls into.



Cantargia AB EV-to-EBITDA Calculation

Cantargia AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=509.931/-224.202
=-2.27

Cantargia AB's current Enterprise Value is kr509.93 Mil.
Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-224.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB  (CHIX:CANTAs) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cantargia AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.174/-1.300
=At Loss

Cantargia AB's share price for today is kr4.174.
Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.300.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Cantargia AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cantargia AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines